Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EBITDA (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed EBITDA for 9 consecutive years, with -$50.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 25.27% to -$50.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$158.1 million through Dec 2025, down 369.49% year-over-year, with the annual reading at -$158.1 million for FY2025, 369.49% down from the prior year.
  • EBITDA hit -$50.4 million in Q4 2025 for Protagonist Therapeutics, down from -$46.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $206.3 million in Q1 2024 to a low of -$67.4 million in Q4 2024.
  • Historically, EBITDA has averaged -$22.5 million across 5 years, with a median of -$36.8 million in 2021.
  • Biggest YoY gain for EBITDA was 672.75% in 2024; the steepest drop was 392.36% in 2024.
  • Year by year, EBITDA stood at -$37.0 million in 2021, then increased by 1.35% to -$36.5 million in 2022, then surged by 163.12% to $23.0 million in 2023, then crashed by 392.36% to -$67.4 million in 2024, then increased by 25.27% to -$50.4 million in 2025.
  • Business Quant data shows EBITDA for PTGX at -$50.4 million in Q4 2025, -$46.4 million in Q3 2025, and -$42.0 million in Q2 2025.